The subgroup analysis of all-cause mortality (S2 Table) indicated that patients taking xanthine oxidase (XO) inhibitors; male patients; patients with underlying stroke without underlying HT, DM, CAD, or hypercholesterolemia; and patients using β-blockers or diuretics not using ACE inhibitors, ARBs, or calcium channel blockers could demonstrate a significantly low risk of all-cause mortality. The gene discussed is ACE; the disease is hematocrit.